The Effectiveness and Tolerability of Topiramate and Lidocaine Add-on Therapy in Children with Refractory Status Epilepticus / 대한소아신경학회지
Journal of the Korean Child Neurology Society
; (4): 72-76, 2014.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-215601
Responsible library:
WPRO
ABSTRACT
PURPOSE:
This study was aimed to compare the effectiveness and tolerability of topiramate add-on therapy versus lidocaine add-on therapy in children with refractory status epilepticus.METHODS:
We performed a retrospective analysis of children with refractory status epilepticus who were hospitalized at Kyungpook National University Hospital during the period 2005 to 2012. We divided them into two groups, Group A (midazolam, MDZ, and Topiramate, TPM11 patients) and Group B (midazolam and lidocaine, LDC7 patients). Furthermore, they were sub-categorized according to children's sex, age, seizure duration, and seizure type. To comepare the effectiveness and tolerability between the two groups, we evaluated seizure freedom, >50% seizure reduction, adverse events and mortality rates, respectively.RESULTS:
In MDZ/TPM group, average dosage of midazolam infusion was 10.8+/-6.8 mcg/kg/min, seizure freedom was achieved in 1 out of 11 patients (9%) and >50% seizure reduction was in 2 out of 11 patients (18%). On the other hand, in MDC/LDC group, average dosage of midazolam infusion is 11.3+/-5.2 mcg/kg/min, seizure freedom was achieved in 2 out of 7 patients (29%) and >50% seizure reduction was 3 out of 7 patients (43%). Aside from the promising effects, there was no significant difference between the two groups.CONCLUSION:
In children with refractory status epilepticus, topiramate or lidocaine add-on therapy seemed to be effective and fairly tolerated and showed no serious adverse effects. Therefore they can be an alternative treatment option. However, further studies are required.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Target 3.2: Reduce avoidable death in newborns and children under 5
/
Epilepsy
Database:
WPRIM (Western Pacific)
Main subject:
Seizures
/
Status Epilepticus
/
Midazolam
/
Retrospective Studies
/
Mortality
/
Freedom
/
Hand
/
Lidocaine
Type of study:
Observational study
/
Prognostic study
Limits:
Child
/
Humans
Language:
Korean
Journal:
Journal of the Korean Child Neurology Society
Year:
2014
Document type:
Article